Managing the burden of chronic kidney disease

Disease Management

Volumn 9, Issue 2, 2006, Pages 115-121

  Thorp, Micah L ^a   Eastman, Loris ^a   Smith, David H ^b   Johnson, Eric S ^b  

^a Kaiser Kidney Program   (United States)

^b Center for Health Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; STATINE DERIVATIVE;

ANEMIA; ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NEPHROLOGIST; OBESITY; PATIENT CARE; PRIMARY MEDICAL CARE; RISK FACTOR;

CONTINUITY OF PATIENT CARE; COST OF ILLNESS; DISEASE MANAGEMENT; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; NEPHROLOGY; PATIENT CARE TEAM; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION; RENAL INSUFFICIENCY, CHRONIC;

EID: 33646520143     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2006.9.115     Document Type: Article

References (34)

1. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998;32:992-999.
2. (Erratum in: Am J Kidney Dis 2000;35:178.)
3. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-2219.
4. McCullough PA. Scope of cardiovascular complications in patients with kidney disease. Ethn Dis. 2002;12:S3-44-48.
5. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003;42:677-684.
6. US Renal Data System. USRDS 2002 annual data report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2002.
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
8. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;165:659-663.
9. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004;15:1300-1306.
10. Trivedi HS, Pang MM, Campbell A, Saab P. Slowing the progression of chronic renal failure: economic benefits and patient's perspectives. Am J Kidney Dis 2002;39:721-729.
11. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005;16:1803-1810.
12. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134.
13. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-1936.
14. Silverberg DS, Wexler D, Blum M, et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001;21:S236-S240.
15. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 1993;43:436-442.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42: S1-S201.
17. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
18. Stack AG. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States. Am J Kidney Dis 2003;41:310-318.
19. Khan SS, Xue JL, Kazmi WH, et al. Does predialysis nephrology care influence patient survival after initiation of dialysis? Kidney Int 2005;67:1038-1046.
20. Wavamunno MD, Harris DC. The need for early nephrology referral. Kidney Int Suppl. 2005:S128-S132.
21. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
22. Verhave JC, Hillege HL, Burgerhof JG, Gansevoort RT, de Zeeuw D, de Jong PE. PREVEND Study Group. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005;67:1967-1973.
23. Landray MJ, Thambyrajah J, McGlynn FJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 2001;38:537-546.
24. Wanner C, Krane V, Marz W, et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.
25. Norris K, Vaughn C. The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. Expert Rev Cardiovasc Ther 2003;1:51-63.
26. Ruggenenti P. Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 2004;24:158-167.
27. Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol 2001;12:1713-1720.
28. American Diabetes Association. Diabetic nephropathy. Position statement. Diabetes Care 2004;27: S79-S84.
29. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotension converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
30. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
31. National Kidney Foundation. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-S290.
32. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000;36:646-661.
33. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278: F817-F822.
34. Wiggins KJ, Johnson DW. The influence of obesity on the development and survival outcomes of chronic kidney disease. Adv Chronic Kidney Dis 2005;12:49-55.